- Cellectis Presents Research Data on a Novel Immune-Evasive Universal CAR T-cell at ASGCT
- Cellectis présente des données de recherche d’une nouvelle cellule CAR T universelle au congrès annuel de l’ASGCT
- Cellectis publie ses résultats financiers du premier trimestre 2022
- Cellectis Provides Business Update and Reports Financial Results for First Quarter 2022
- Information mensuelle relative au nombre total des droits de vote et d’actions composant le capital social
- Monthly information on share capital and company voting rights
- Cellectis annonce ses résultats financiers pour le premier trimestre 2022
- Cellectis to Report First Quarter 2022 Financial Results
- Calyxt, Inc., Cellectis’ Majority-Owned Subsidiary, Reports Its First Quarter 2022 Financial Results
- Cellectis Publishes Two Articles in Nature Communications Providing Strong Preclinical Validation of UCART123 to Treat AML and BPDCN
More ▼
Key statistics
As of last trade, Cellectis SA (ZVAA:STU) traded at 3.14, 31.93% above the 52 week low of 2.38 set on May 10, 2022.
52-week range
Markit short selling activity
Open | 2.96 |
---|---|
High | 3.16 |
Low | 2.86 |
Bid | 3.38 |
Offer | 4.02 |
Previous close | 2.96 |
Average volume | 60.80 |
---|---|
Shares outstanding | 45.48m |
Free float | 45.48m |
P/E (TTM) | -- |
Market cap | 152.33m USD |
EPS (TTM) | -2.97 USD |
Data delayed at least 15 minutes, as of May 19 2022.
More ▼